{
    "nct_id": "NCT04446260",
    "official_title": "A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects",
    "inclusion_criteria": "* Advanced/unresectable or metastatic solid tumor with HER2 expression or mutation that is refractory to or intolerable with standard treatment, or for which no standard treatment is available\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* LVEF â‰¥ 50% by either ECHO or MUGA\n* Has adequate renal and hepatic function\n* Female subjects agree not to be pregnant or lactating from beginning of the study screening until 6 months after receiving the last treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected to have these diseases by imaging at screening period\n* Known hereditary or acquired bleeding and thrombotic tendency",
    "miscellaneous_criteria": ""
}